Hopes for the development of an\r\neffective vaccine to protect tilapia from Streptococcus have been given a boost\r\nfollowing the publication of the results of a new study. Streptococcus agalactiae ...
Hopes for the development of an\r\neffective vaccine to protect tilapia from Streptococcus have been given a boost\r\nfollowing the publication of the results of a new study.
Streptococcus agalactiae is\r\none of the most widespread bacterial pathogens impacting the international\r\ntilapia farming sector, causing great losses of intensive tilapia farming –\r\nwith the value of losses incurred in China (the world’s largest producer of the\r\nspecies) estimated at up to $1.5 billion a year.
Outbreaks of the disease are\r\ngenerally dealt with through the use of antibiotics, but a vaccine is seen as a\r\npreferable method for numerous reasons – not least due to fears of the spread\r\nof antibiotic resistance and because it leads to an imbalance of bacterial\r\nmicrobiota both within the fish and their habitat. The results of the study,\r\nled by researchers from the School of Life Sciences at Sun Yat‐Sen\r\nUniversity, have been published in the latest issue of the Journal of\r\nFish Diseases.
In order to develop a potential\r\nlive attenuated vaccine, the researchers developed a re‐attenuated S.\r\nagalactiae (named TFJ‐ery) from a natural low‐virulence S. agalactiae strain\r\nTFJ0901 through selection of resistance to erythromycin.
When Nile tilapia were\r\nintraperitoneally injected with TFJ‐ery, the mortality of fish was decreased,\r\nwhile the RPS of fish immunized with TFJ‐ery at a dose of 5.0 × 107CFU was\r\n95.00%, 93.02% and 100.00% at 4, 8 and 16 weeks post‐vaccination, respectively.\r\nELISA results showed that the vaccinated fish produced significantly higher (p\r\n
Ditulis oleh
Tim Minapoli
Kontributor
Pakar di bidang akuakultur dengan pengalaman lebih dari 15 tahun. Aktif berkontribusi dalam pengembangan industri perikanan Indonesia.